213 related articles for article (PubMed ID: 23377402)
21. Dermatology of androgen-related disorders.
Essah PA; Wickham EP; Nunley JR; Nestler JE
Clin Dermatol; 2006; 24(4):289-98. PubMed ID: 16828411
[TBL] [Abstract][Full Text] [Related]
22. Androgen action on human skin -- from basic research to clinical significance.
Zouboulis CC; Degitz K
Exp Dermatol; 2004; 13 Suppl 4():5-10. PubMed ID: 15507105
[TBL] [Abstract][Full Text] [Related]
23. Selective non-steroidal inhibitors of 5 alpha-reductase type 1.
Occhiato EG; Guarna A; Danza G; Serio M
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):1-16. PubMed ID: 15026079
[TBL] [Abstract][Full Text] [Related]
24. [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?].
Spinucci G; Pasquali R
Clin Ter; 1996 Jun; 147(6):305-15. PubMed ID: 8925640
[TBL] [Abstract][Full Text] [Related]
25. Antiandrogen therapy for skin and hair disease.
Harper JC
Dermatol Clin; 2006 Apr; 24(2):137-43, v. PubMed ID: 16677962
[TBL] [Abstract][Full Text] [Related]
26. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
27. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
28. [Use of anti-androgens in skin diseases].
Nolting S
Z Hautkr; 1979 Jun; 54(12):529-32. PubMed ID: 88827
[No Abstract] [Full Text] [Related]
29. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
[TBL] [Abstract][Full Text] [Related]
30. [Clinical use of antiandrogens (author's transl)].
Rüedi B
Ther Umsch; 1979 Oct; 36(10):904-7. PubMed ID: 161082
[No Abstract] [Full Text] [Related]
31. [Dermatologic indications for anti-androgenic treatment].
Zaun H; Ludwig E
Z Hautkr; 1978 Nov; 53(21):759-65. PubMed ID: 82309
[TBL] [Abstract][Full Text] [Related]
32. Androgens in women: Androgen-mediated skin disease and patient evaluation.
Bienenfeld A; Azarchi S; Lo Sicco K; Marchbein S; Shapiro J; Nagler AR
J Am Acad Dermatol; 2019 Jun; 80(6):1497-1506. PubMed ID: 30312644
[TBL] [Abstract][Full Text] [Related]
33. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
34. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
35. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
Burke BM; Cunliffe WJ
Br J Dermatol; 1985 Jan; 112(1):124-5. PubMed ID: 3155956
[No Abstract] [Full Text] [Related]
36. [Hormonal assessment in a woman with acne and alopecia].
Faure M; Drapier-Faure E
Rev Fr Gynecol Obstet; 1992 Jun; 87(6):331-4. PubMed ID: 1385888
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Lynn R; Krunic A
Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
[TBL] [Abstract][Full Text] [Related]
38. Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells.
Lee HH; Ho CT; Lin JK
Carcinogenesis; 2004 Jul; 25(7):1109-18. PubMed ID: 14963012
[TBL] [Abstract][Full Text] [Related]
39. [Anti-androgens. Their use in dermatology].
Montero ED; Arevalo A; Michelotti M
Med Cutan Ibero Lat Am; 1981; 9(4):275-84. PubMed ID: 6456390
[TBL] [Abstract][Full Text] [Related]
40. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
